Storia in 3 fonti

Qureight secures $20M Series B to expand AI-powered imaging platform for clinical trials

Series B funding will accelerate development of new AI disease models for lung and heart conditions, while expanding the company's imaging analytics platform.

Raccontata da

techfundingnews.com

tech.eu

thenextweb.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

tech.euStai leggendo6 g fa

Qureight secures $20M Series B to expand AI-powered imaging platform for clinical trials

Qureight raccoglie $20M Serie B per piattaforma AI imaging clinical trials con foundation model 3D. Abilita synthetic control arms, riduce costi/tempi trial ed espande in asthma/pulmonary hypertension, consolidando leadership in imaging CRO per biopharma.

originale

techfundingnews.com6 g fa

Exclusive: Cambridge's Qureight raises $20M to bring AI to lung and heart clinical trials — TFN

Qureight raised $20M Series B for AI imaging in clinical trials, cutting turnaround from two weeks to 48 hours. Automating imaging analysis cuts pharma's R&D bottleneck, compressing drug development cycles and accelerating time-to-market for new therapeutics.

Qureight secures $20M Series B to expand AI-powered imaging platform for clinical trials

Confronto fonti

Qureight secures $20M Series B to expand AI-powered imaging platform for clinical trials

Exclusive: Cambridge's Qureight raises $20M to bring AI to lung and heart clinical trials — TFN

Timeline cronologica

Exclusive: Cambridge's Qureight raises $20M to bring AI to lung and heart clinical trials — TFN

Qureight secures $20M Series B to expand AI-powered imaging platform for clinical trials

Qureight raises $20m for a chest AI to speed drug trials

Qureight raises $20m for a chest AI to speed drug trials